

CLAIM AMENDMENTS

Claims 1 - 23 (Canceled)

24. (Currently amended) A method of making a granular pharmaceutical formulation product consisting essentially of:

combining at least one lipophilic pharmaceutically active agent with at least one phospholipid in a non-aqueous solvent ~~to produce a granular preliposomal combination~~, wherein said pharmaceutically active agent is a poorly water soluble drug;

evaporating said non-aqueous solvent to produce a powder; and

applying an enteric coating material to said ~~pharmaceutically active agent and said phospholipid powder to produce a granular product~~, wherein said enteric coating is in contact with at least a portion of said ~~preliposomal combination powder~~; and

forming said coated granular product into a dosage form selected from the group consisting of one or more of the following: a capsule, or suspension and tablet.

25. (Canceled)

26. (Currently amended) The method of Claim 24, wherein said pharmaceutically active agent is selected from the group consisting of one or more of the following: griseofulvin, famotidine, meclizine, cyclosporine, carbamazepine, methotrexate, itraconazole, dipyridamole, mercaptopurine, halofantrine, amiodarone, lomustine, testosterone, and misoprostil, etoposide, rifamycin, azathioprine, glyburide, tolbutamide, aminoglutethimide, taxol, clofibrate, nifedipine, methyl dopa, ramipril and dicumarol.

27. (Original) The method of Claim 24, wherein said phospholipid is a phosphatidyl phospholipid.

28. (Currently amended) The method of Claim 24, wherein said phospholipid is selected from the group consisting of one or more of the following: distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, egg PC, soy PC, DMPG, DMPA, DPPG, DPPA, DSPG, DSPA, phosphatidylserine and sphingomyelin.

29. (Currently amended) The method of Claim 24, wherein said enteric coating material is selected from the group consisting of one or more of the following: cellulose

acetate phthalate, alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, methacrylate-methacrylic acid copolymers, polyvinyl acetate phthalate and styrol maleic acid copolymers.

30. (Currently amended) The method of Claim 24, wherein said applying an enteric coating material comprises spraying said ~~pharmaceutically active agent and said phospholipid powder~~ with said enteric coating material.

31. (Canceled)

32. (Canceled)

33. (Canceled)

34. (Canceled)

35. (Canceled)

36. (Canceled)

37. (Currently amended) A method for delivering the pharmaceutical formulation produced by the method of Claim 24 to a mammal comprising orally administering said granular pharmaceutical product ~~formulation~~ to said mammal.

38. (Currently amended) A method for diagnosing or treating an illness in a mammal comprising administering the granular pharmaceutical product ~~formulation~~ produced by the method of Claim 24.

39. (Canceled)

40. (Canceled)

41. (Currently amended) The method of Claim 38, wherein said granular pharmaceutical product ~~agent~~ is administered at a biologically active dose.

42. (Currently amended) The method of Claim 38, wherein said ~~proliposomal combination~~ granular pharmaceutical product forms liposomes in the mammal's gastrointestinal tract.